Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma

MLA

Caroline Robert, et al. “Update on Overall Survival in COLUMBUS: A Randomized Phase III Trial of Encorafenib (ENCO) plus Binimetinib (BINI) versus Vemurafenib (VEM) or ENCO in Patients with BRAF V600-Mutant Melanoma.” Journal of Clinical Oncology, vol. 38, May 2020, p. 10012. EBSCOhost, https://doi.org/10.1200/jco.2020.38.15_suppl.10012.

APA

Caroline Robert, Paolo A. Ascierto, Gabriella Liszkay, Michael D Pickard, Helen Gogas, Caroline Dutriaux, Mario Mandalà, Ralf Gutzmer, Claus Garbe, Jan Willem B. de Groot, Ashwin Gollerkeri, Keith T. Flaherty, Ivana Krajsová, Reinhard Dummer, Ana Arance, Dirk Schadendorf, & Carmen Loquai. (2020). Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. Journal of Clinical Oncology, 38, 10012. https://doi.org/10.1200/jco.2020.38.15_suppl.10012

Chicago

Caroline Robert, Paolo A. Ascierto, Gabriella Liszkay, Michael D Pickard, Helen Gogas, Caroline Dutriaux, Mario Mandalà, et al. 2020. “Update on Overall Survival in COLUMBUS: A Randomized Phase III Trial of Encorafenib (ENCO) plus Binimetinib (BINI) versus Vemurafenib (VEM) or ENCO in Patients with BRAF V600-Mutant Melanoma.” Journal of Clinical Oncology 38 (May): 10012. doi:10.1200/jco.2020.38.15_suppl.10012.